Alex Zhavoronkov, PhD

Dr. Alex Zhavoronkov is the CEO of Insilico Medicine, a leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research, and one of the Longevity Science Foundation’s Scientific Advisory Board members.

At Insilico, Alex pioneered generative adversarial networks and reinforcement learning techniques for generating novel molecular structures with the desired properties. He set up the R&D centers in 6 countries, including Korea, Russia, and Taiwan and launched multiple biomarker initiatives, including Young.AI.

Before founding Insilico Medicine, Alex worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI. He also created AgeNet.net, a platform with contests, hackathons and resources for aging biomarker development competitions and led diversity.AI initiative.

Since 2012 he has published over 80 peer-reviewed research papers and books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's most significant industry events in drug discovery.

Dr. Zhavoronkov holds two Bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.